Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Nurix Therapeutics (NRIX) over the last 4 years, with Aug 2024 value amounting to $9.5 million.

  • Nurix Therapeutics' Long-Term Investments fell 4.15% to $9.5 million in Q3 2024 from the same period last year, while for Aug 2024 it was $9.5 million, marking a year-over-year decrease of 4.15%. This contributed to the annual value of $7.4 million for FY2023, which is 88.38% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Long-Term Investments of $9.5 million as of Q3 2024, which was up 0.98% from $9.4 million recorded in Q2 2024.
  • Nurix Therapeutics' 5-year Long-Term Investments high stood at $137.2 million for Q4 2021, and its period low was $7.4 million during Q4 2023.
  • Moreover, its 3-year median value for Long-Term Investments was $27.5 million (2023), whereas its average is $39.1 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 17,862.45% in 2020, then tumbled by 88.38% in 2023.
  • Nurix Therapeutics' Long-Term Investments (Quarterly) stood at $90.9 million in 2020, then surged by 50.94% to $137.2 million in 2021, then plummeted by 53.44% to $63.9 million in 2022, then crashed by 88.38% to $7.4 million in 2023, then dropped by 4.15% to $9.5 million in 2024.
  • Its Long-Term Investments was $9.5 million in Q3 2024, compared to $9.4 million in Q2 2024 and $10.3 million in Q1 2024.